| Line Item | 2025-03-31 | Y/Y |
|---|---|---|
| R&D Expense | $9.5M | +103.1% |
| SG&A Expense | $7.2M | +11.4% |
| Operating Income | -$16.7M | -29.8% |
| Pre-tax Income | -$12.8M | +13.1% |
| Income Tax | -$3.2M | -74.6% |
| Net Income | -$9.6M | +25.6% |
| EPS (Basic) | -$0.79 | +41.5% |
| EPS (Diluted) | -$0.79 | +41.5% |
| Line Item | 2025-03-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $22.1M | -3.8% |
| Current Assets | $22.7M | -5.4% |
| Total Assets | $72.0M | -1.8% |
| Current Liabilities | $1.9M | +14.6% |
| Total Liabilities | $5.4M | -53.4% |
| Stockholders' Equity | $66.6M | +7.9% |
| Line Item | 2025-03-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$14.9M | -20.8% |
| Investing Cash Flow | $0 | -100.0% |
| Financing Cash Flow | $14.0M | +90.7% |